TABLE 1.

Cell-mediated immunity at the time point after the suspension of antiviral prophylaxis (1 or 3 months posttransplant) and before the onset of CMV infection (15 days posttransplant [Tbio]) in the preemptive strategy group^a

Infection status	No. (%) of patients with indicated QFN-CMV results
	Prophylaxis strategy group				Preemptive strategy group
	Indeterminate	Negative/positive	NA	Total	Indeterminate	Negative/Positive	NA	Total
Patients who developed CMV infection	6 (66.7)	1 (14.3)	0 (0.0)	7 (41.2)	10 (55.6)	4 (66.7)	3c (100.0)	17 (63.0)
Patients who did not develop CMV infection	3 (33.3)	6 (85.7)	1b (100.0)	10 (58.8)	8 (44.4)	2 (33.3)	0 (0.0)	10 (37.0)
Total	9	7	1	17	18	6	3	27

^aThe immunological results were retrospectively analyzed in relation to the development of posttransplant CMV infection. NA, not available.

^bBlood sample was not collected.

^cPatients developed CMV infection within 6 days posttransplant.